organization · Reporting owner

FHM VI, L.L.C.

Disclosed activity across 3 companies

Tapewire entity: 161859
SEC CIK: 0001456654

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allena Pharmaceuticals, Inc.ALNA · Entity 130904	10% owner	November 06, 2017	November 06, 2017
Sierra Oncology, Inc.SRRA · Entity 125698	10% owner	February 14, 2017	February 24, 2017
Tempest Therapeutics, Inc.MLND · Entity 7734	10% owner	December 07, 2018	December 11, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allena Pharmaceuticals, Inc.

Report date November 06, 2017 · Filed November 06, 2017

Jointly reported with FHM VI, L.P., Frazier Healthcare VI, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Healthcare VI, L.P.	3,330,373	Last balance in matching sequence After 2017-11-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-11-06 · Conversion · Acquired 2,830,373 · Balance 2,830,373 F1: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F2: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F3: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Row 2 · 2017-11-06 · Purchase · Acquired 500,000 · Balance 3,330,373 F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectBy Frazier Healthcare VI, L.P.	0	Reported balance After 2017-11-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-06 · Conversion · Disposed 6,122,448 · Balance 0 F1: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Frazier Healthcare VI, L.P.	0	Reported balance After 2017-11-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-11-06 · Conversion · Disposed 4,629,630 · Balance 0 F2: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Frazier Healthcare VI, L.P.	0	Reported balance After 2017-11-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-11-06 · Conversion · Disposed 1,061,904 · Balance 0 F3: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5: Not applicable. F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.

F2: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.

F3: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer.

F4: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.

F5: Not applicable.

Sierra Oncology, Inc.

Report date February 14, 2017 · Filed February 24, 2017

Jointly reported with Frazier Healthcare VI, L.P., FHM VI, L.P., Frazier Life Sciences VIII, L.P., FHM LIFE SCIENCES VIII, L.P., FHM LIFE SCIENCES VIII, L.L.C., FRAZIER ALAN D, Naini Nader J, Every Nathan R, Heron Patrick J

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,186,195	Reported balance Holding disclosure · report date 2017-02-14 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,186,195 F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	Direct	5,925,926	Reported balance Holding disclosure · report date 2017-02-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 5,925,926 F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held by Frazier Healthcare VI, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

F2: Represents shares held by Frazier Life Sciences VIII, L.P., an affiliate of Frazier Healthcare Partners. Each of the Reporting Persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.

Tempest Therapeutics, Inc.

Report date December 07, 2018 · Filed December 11, 2018

Jointly reported with FHM VI, L.P., Frazier Healthcare VI, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Frazier Healthcare VI, L.P.	1,396,615	Reported balance Holding disclosure · report date 2018-12-07 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,396,615 F1: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 06, 2017 Filed Nov 6, 2017 18:46 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries C Preferred Stock · Derivative	1,061,904	$0.00	$0.00	Disclosure SEC source: 0001209191-17-059504 · doc4.xml · derivative · entry 5 FHM VI, L.L.C. · CIK 0001456654 · 10% owner FHM VI, L.P. · CIK 0001456655 · 10% owner Frazier Healthcare VI, L.P. · CIK 0001456656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 254,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5 · derivative.expiration_date: Not applicable. F4 · ownership.nature: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Read SEC document
November 06, 2017 Filed Nov 6, 2017 18:46 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries B Preferred Stock · Derivative	4,629,630	$0.00	$0.00	Disclosure SEC source: 0001209191-17-059504 · doc4.xml · derivative · entry 4 FHM VI, L.L.C. · CIK 0001456654 · 10% owner FHM VI, L.P. · CIK 0001456655 · 10% owner Frazier Healthcare VI, L.P. · CIK 0001456656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,109,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5 · derivative.expiration_date: Not applicable. F4 · ownership.nature: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Read SEC document
November 06, 2017 Filed Nov 6, 2017 18:46 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionSeries A Preferred Stock · Derivative	6,122,448	$0.00	$0.00	Disclosure SEC source: 0001209191-17-059504 · doc4.xml · derivative · entry 3 FHM VI, L.L.C. · CIK 0001456654 · 10% owner FHM VI, L.P. · CIK 0001456655 · 10% owner Frazier Healthcare VI, L.P. · CIK 0001456656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,466,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F5 · derivative.expiration_date: Not applicable. F4 · ownership.nature: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Read SEC document
November 06, 2017 Filed Nov 6, 2017 18:46 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	PurchaseCommon Stock	500,000	$14.00	$7,000,000.00	Disclosure SEC source: 0001209191-17-059504 · doc4.xml · nonDerivative · entry 2 FHM VI, L.L.C. · CIK 0001456654 · 10% owner FHM VI, L.P. · CIK 0001456655 · 10% owner Frazier Healthcare VI, L.P. · CIK 0001456656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VI, L.P. Disclosed balance after: 3,330,373 F4 · ownership.nature: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Read SEC document
November 06, 2017 Filed Nov 6, 2017 18:46 UTC	Allena Pharmaceuticals, Inc. ALNA · Entity 130904	ConversionCommon Stock	2,830,373	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-059504 · doc4.xml · nonDerivative · entry 1 FHM VI, L.L.C. · CIK 0001456654 · 10% owner FHM VI, L.P. · CIK 0001456655 · 10% owner Frazier Healthcare VI, L.P. · CIK 0001456656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Frazier Healthcare VI, L.P. Disclosed balance after: 2,830,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F2 · price: The Series B Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F3 · price: The Series C Preferred Stock automatically converted into Common Stock of the Issuer on a 4.174-to-1 basis upon closing of the initial public offering of the Issuer. F4 · ownership.nature: The securities are held by Frazier Healthcare VI, L.P. ("Frazier VI"). FHM VI, L.P. ("FHM LP") is the general partner of Frazier VI and FHM VI, L.L.C. ("FHM LLC") is the general partner of FHM LP. Each of FHM LLC and FHM LP disclaims beneficial ownership of all shares held by Frazier VI except to the extent, if any, of such entity's, as applicable, pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.